With AMI Buy, Angiotech Looks To Become Less Reliant On Partnerships
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals' $785 mil. acquisition of American Medical Instruments Holdings will allow the firm to diversify its revenue stream and retain more control over its combination product business